Know Your Benefits
Visit Community Corner
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer announced that they've started testing the safety profile of their novel oral antiviral investigational drug candidate for SARS-CoV-2 infections.
Read the full article.
Copyright © 2021 Pfizer Inc All Rights Reserved |